The global nucleic acid therapeutics market is predicted to surpass the market size of US$ 9 Billion by 2028; registering a CAGR of 19.5% during the forecast period from 2021- 2028.
Nucleic Acids or their closely associated compound are used for the treatment of unmet medical needs. Such acids are skilled to target at the genetic level (RNA and DNA) preventing the aspect of disease-causing problems.
Accelerating towards more innovative biologic and cell & gene therapy products have shifted towards the demand for nucleic acid therapeutics market. Nuclei-based therapy is also used for the treatment of numerous diseases like cancer, AIDS, tuberculosis, cardiovascular diseases, and diabetes. With the introduction of nucleic acid-based therapeutics, treatment for problematic ailments has become graceful and effort-free. Moreover, the growth of ailments for the genetic disease is sluggish, and only fewer treatments are present to cure genetic diseases. Such acid-based therapeutics treats inactive genes present in the body and works with the body molecules for treating such disorders via combing with the gene sequence for its treatment.
The software-based therapeutics market is increasing the market growth and is expected to become favorable for the health sector. Precise mapping of the molecular structure of the human body and increasing more intensive research & development (R&D) for the treatment of gene disorders will provide scope for the nuclei acid-based therapeutics market. However, higher costs associated with research and higher failure rates is the factor restraining the growth of the global market. In addition, changes in genetic level and its contamination leads to difficulties in finding effective treatments also prohibit the global market growth.
The Global Nucleic Acid Therapeutics Market report analysis is segmented by technology, application, structure, end- usage, and region. By technology, the market is categorized into microarrays, QRT-PCR, inhibition, linear amplification, antisense antigen, short inhibitory sequence, nucleoside analogs, purification, aptamers, ribozymes, and gene transfer therapy. Based on application, the report segments into cardiovascular disease, neurogenetic disorders, cancer diabetes, haemophilia, monogenetic disorders, thalassemia, and cystic fibrosis. By structure, the global nucleic-acid therapeutics market is categorized into single-stranded RNA/DNA and double-stranded DNA. The End-usage segment bifurcates into research institutes, hospitals, and others.
Based on geography, the report is classified into North America (U.S, Canada), Europe (Germany, France, UK, Russia, Spain, Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Rest of Asia Pacific), Rest of the World (Latin America and the Middle East & Africa). Geographically, North America holds the highest market share owing to the R&D of new drugs & technologies associated with it and the increasing healthcare expenditure. The Asia Pacific is also predictable to grasp in the upcoming years owing to extensive research and development and minimal research cost in the forecast period. Government support in the European region aims to garner the demand for the nucleic-acid therapeutics market revenue growth.
Prominent players inducing the Global Nucleic-Acid Therapeutics Market are agtc, Wave Life Science Ltd., Imugene, Aileron Therapeutics Inc., Akcea Therapeutics, BioNTech SE, Biocon, Biomedica, Protagonist Therapeutics Inc., Replicate Bioscience Inc., Eli Lily and Company, Copernicus Therapeutics Inc., Invio Pharmaceuticals Inc., Benitec Biopharma, Alnylam Pharmaceuticals, Zydus Cadila, Excision BioTherapeutics, Pfizer Inc., Rhythm Pharmaceuticals Inc., and Axcella Health Inc., among others.
Segmentation and Scope of the Global Nucleic Acid Therapeutics Market
The Global Nucleic Acid Therapeutics Market is segmented by Technology, Application, Structure, End-Use, and Region.
Prominent players in the Global Nucleic Acid Therapeutics Market